Adaptin Bio (APTN) Operating Expenses (2023 - 2026)

Adaptin Bio has disclosed Operating Expenses across 4 years of filings, most recently posting $1.1 million for Q1 2026.

• Quarterly Operating Expenses rose 34.53% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 82.93% YoY) and the FY2025 annual result came in at $5.4 million, up 110.71% from the prior year.
• Operating Expenses retreated to $1.1 million in Q1 2026, from $1.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $1.7 million in Q3 2025 and bottomed at $4250.0 in Q1 2023.
• The 4-year median for Operating Expenses is $767320.0 (2024), against an average of $708813.4.
• Year-over-year, Operating Expenses surged 17954.59% in 2024 and surged 34.53% in 2026.
• Adaptin Bio's Operating Expenses stood at $34155.0 in 2023, then jumped by 1387.57% to $508080.0 in 2024, then surged by 169.25% to $1.4 million in 2025, then slipped by 16.36% to $1.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $1.1 million, $1.4 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.